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In Alzheimer’s disease, the most characteristic neuropathological changes are the formation of neurofibrillary tangles 
(NFT) and neuritic plaques (NP) characterized by the presence of bundles of paired helical filaments (PHF) that accumu- 
late in the degenerating neurites and neuronal cell bodies. Although the protein composition of the PHF is ill-defined, 
a number of microtubule-associated proteins have been implicated in these lesions. Here we report results with an antise- 
rum monospecific for the microtubule-associated protein MAP 2 which does not cross-react with any other microtubular 
protein. Immunostaining with this antibody of sections from an Alzheimer’s brain show a strong reactivity with NFT 
but no reactivity at the level of the NP. On the other hand, immunostaining of Alzheimer’s brain sections with another 
antibody specific for the microtubule-associated protein r shows strong staining of PHF on both NFT and NP. These 
findings confirm the presence of the 5 proteins in the PHF and strongly suggest hat MAP 2 may not be a main structural 
component of the PHF. Labelling of NFT with the anti-MAP 2 antiserum suggests a non-specific binding of MAP 2 
to the PHF during the process of NFT formation. 
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1. INTRODUCTION 
People with Alzheimer’s disease show neuro- 
degenerative abnormalities characterized by the 
presence of cortical lesions consisting mainly of in- 
traneuronal NFT and senile NP [l]. Electron 
microscopic studies have shown that both NFT 
and NP contain PHF [2] formed by eight pro- 
tofilaments slightly larger in diameter than normal 
neurofilaments and which are composed of pro- 
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teins arranged in &pleated sheets [3]. The iden- 
tification of the components of the PHF has been 
the subject of a number of investigations but these 
studies have been hampered by the difficulties in 
isolating and solubilizing these lesions. Different 
studies using chemical and immunochemical 
methods indicate that 7 proteins, a heterogenous 
group of microtubule-associated proteins, could be 
one of the main constituents of the PHF [4-71. 
More recently molecular genetic studies have con- 
firmed the presence of 7 in PHF [8,9]. On the other 
hand, there is a controversy as to whether the high- 
molecular-mass protein MAP 2 is an actual com- 
ponent of PHF. Using a polyclonal antibody 
which specifically reacts with MAP 2, the present 
study demonstrates no reactivity at the level of the 
NP while an antibody specific for 7 shows strong 
labelling of these lesions supporting the idea that 7 
forms part of the PHF but that MAP 2 does not. 
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2. MATERIALS AND METHODS 
2.1. Brain extracts 
Rat brain soluble extracts or thermostable MAPS were 
prepared as described previously [lo]. To prepare soluble ex- 
tracts from normal or Alzheimer’s human brains, approximate- 
ly 10 g of tissue from the frontal cortex were frozen and 
reduced to powder under liquid nitrogen. After resuspending 
the powder in buffer D (see [lo]) at 37°C a soluble extract was 
prepared following the procedure used to prepare the rat brain 
extract [lo]. 
2.2. Gel electrophoresti 
Approximately 150 pg of protein were loaded on 7.5% SDS- 
polyacrylamide gels and electrophoresed using the system 
described by Laemmli [ 111. Molecular masses were determined 
using a standard mixture obtained from Pharmacia. The gels 
were fixed with 30% methanol, 7% acetic acid and stained with 
0.15% Coomassie brilliant blue. 
2.3. Preparation and characterization of the antibodies 
The anti-MAP 2 antibody was prepared as described 1121. 
Briefly, microtubule proteins [lo] were submitted to elec- 
trophoresis and stained. The band corresponding to MAP 2 was 
excised, homogenized in PBS and used for the production of 
MAP 2 antiserum by immunizing New Zealand White rabbit. 
The preparation and characterization of the anti-r antibody has 
been described elsewhere [13,14]. Analysis of the specificity of 
the antibodies was achieved after improved transfer of MAP 2 
as well as other proteins to nitrocellulose sheets by diffusion 
blots as follows. After the brain extracts had been elec- 
trophoresed, the gel was sandwiched between two sheets of 
nitrocellulose paper followed by 3 sheets of Whatmann 3MM 
paper. The entire sandwich was placed between sponges and 
held together by perforated stainless teel plates firmly clamped 
and immersed for 48 h in a pH 8.0 buffer containing 10 mM 
Tris-HCl, 50 mM NaCI, 2.0 mM EDTA, 0.1 mM PMSF and 
10 mM&mercaptoethanol. In this manner, we obtained a more 
effective transfer of the high-molecular-mass proteins. Two 
nitrocellulose sheets containing the blotted proteins can be ob- 
tained from a single gel. Immunostaining was done as described 
[15]. For competition experiments the anti-MAP 2 antibody 
was preincubated with purified (rat) MAP 2 for 1 h before in- 
cubation of the blot. 
2.4. Immunolabelling of brain sections 
The immunohistochemistry was done on adjacent sections of 
Alzheimer’s brain as previously described [7] on paraffin 
embedded samples. 
3. RESULTS AND DISCUSSION 
Given that a number of reports have shown that 
mAb [17] prepared against neurofilament proteins 
[ 16,171 show varying degrees of cross-reaction with 
microtubular proteins, we investigated, by im- 
munoblot analysis, the specificity of our anti-MAP 
2 antibody. For this we used heavily loaded gels 
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containing whole brain extracts from rat and 
Alzheimer’s brains. As seen in fig.lB, the anti- 
MAP 2 antiserum shows a strong reaction with a 
band present in rat brain MAPS (fig.lA) cor- 
responding in size to MAP 2 (a doublet correspon- 
ding to MAP 2 a and b can be seen in 
non-overloaded gels, data not shown) and shows 
no reactivity with the proteins in the r region. 
Several reports have shown that human MAP 2 
rat human 
MAP2, 
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Fig. 1. SDS-polyacrylamide electrophoresis and immunoblots of 
various brain extracts. (A) 5Opg of rat brain thermostable 
MAPS stained with Coomassie blue; (B) immunoblot of the 
same extract shown in A after reaction with the anti-MAP 2 
antibody; (C) immunoblot of the same extract shown in A after 
absorption of the anti-MAP 2 antibody with 50pg/ml of 
purified rat brain MAP 2; (D) 150,~g of brain soluble extract 
from an Alzheimer’s brain stained with Coomassie blue; (E) 
immunoblot of the same extract shown in D after reaction with 
anti-MAP 2 antibody; (F) immunoblot of the same extract 
shown in D after absorption of the anti-MAP 2 antibody with 
50pg/ml of purified rat brain MAP 2; (G) 150,ug of brain 
extract from an 85-year-old woman brain stained with 
Coomassie blue; (H) immunoblot of the same extract shown in 
G after reaction with anti-MAP 2 antibody; arrowheads point 
to either the 300 kDa MAP 2 protein e) or peptides of smaller 
size produced by MAP 2 proteolysis (4). All immunoblots were 
done with the antiserum diluted 1: 500 in PBS. 
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is highly sensitive to proteolysis giving rise in gels 
to several small size peptides [18]. In agreement 
with this, Alzheimer’s brain extracts (fig.lD) and 
normal human brain extracts from a 85 year old 
woman (fig.lG), present no major protein band 
corresponding to MAP 2. The corresponding im- 
munoblots show only positive reactivity with a 
number of smaller peptides (fig. 1E). The high level 
of MAP 2 proteolysis is mainly due to the time 
elapse between the death of the patient and the 
autopsy. In order to insure that the bands 
recognized by this serum actually derive from 
MAP 2 and not from cross-reacting peptides we 
performed absorption experiments of the an- 
tiserum with purified rat MAP 2. As seen in fig. 1, 
lanes C and F, the reactivity of the serum against 
both the rat and Alzheimer’s proteins is almost 
completely abolished by this treatment. Taken 
together these data confirm the highly specific 
nature of the anti-MAP 2 antiserum as well as the 
fact that it is capable of recognizing a number of 
different MAP 2 epitopes in Alzheimer’s brain. 
This antibody thus represents an excellent ool for 
studying the presence of MAP 2 determinants in 
PHF. 
The knowledge of the protein composition of 
Fig.2. Immunostaining of sections of Alzheimer’s brain hippocampus. Staining of NPT on two adjacent sections: (A) with the human 
anti-7 antibody; (B) with the anti-MAP 2 antibody. Staining of NP on two adjacent sections: (C) with the anti-r antibody; (D) with 
the anti-MAP 2 antibody. Arrows in A and B show Iabelled NFT. Arrows in C show the labelled neuritic plaques. In all experiments 
antibodies were diluted 1: 1000 in PBS. 
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the PHF, the main component of both the NFT 
and NP in Alzheimer’s patients, should be the ma- 
jor aim if one wishes to understand the etiology of 
this disease. Immunological studies have identified 
several microtubular proteins as components of 
the PHF [5,6,8,18]. Among these, both MAP 2 
[17] and 7 have been signalled as forming part of 
the NFT. We have previously prepared an anti- 
NFT antiserum that reacts only with the 
microtubule-associated protein 7 and that does not 
cross-react with MAP 2 [13]. Using this antibody 
for in situ staining of sections from an Alzheimer’s 
brain we demonstrate here that both NFT (fig.2A) 
and NP (fig.2C) are marked by this antibody, con- 
firming previous reports that show that 7 or some 
of its fragments form part of the PHF [5,6,8,13]. 
In separate experiments using a monoclonal an- 
tibody specific for 7 proteins we have confirmed 
the presence of these proteins in both PHF and 
NFT (data not shown). On the other hand, using 
our MAP 2-specific antiserum we demonstrate the 
absence of MAP 2 epitopes in the NP (fig.2B). 
However, adjacent sections show that NFT are 
labelled with this antibody (fig.2D). Since PHF 
have been clearly identified in both NP and NFT 
[2,3] the presence of MAP 2 epitopes in one and 
not in the other, as shown here, may appear dif- 
ficult to reconcile. However, this can be inter- 
preted as MAP 2 being a contaminant in the NFT 
rather than an actual constituent of it. This inter- 
pretation is supported by reports showing that 
MAP 2 may bind nonspecifically to NFT [22,23] or 
that it may be trapped inside the lesions due to the 
abundance of MAP 2 in the neuronal cell body 
[24-261. This will not be the case for the NP since 
no MAP 2 has been described to be present in 
degenerating axonal neurites. Although some in- 
vestigators have reported the presence of MAP 2 
epitopes in PHF using mAbs [24], more recent fin- 
dings seem to indicate that this could be due to 
cross-reaction with 7 [20]. This interpretation is 
strengthened by the present data, also confirmed 
by others [4-6,9] that show that 7 is part of the 
Alzheimer’s lesions. However, one cannot rule out 
the possibility that the composition of PHF in 
NFT and NP may differ by a molecule present in 
NFT and characterized by a nonspecific affinity 
for MAP 2. 
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